Director Olivia Ware executed a sale of 9,000 shares of Arcellx Inc (ACLX, Financial) on March 15, 2024, according to a recent SEC filing. The transaction was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Arcellx Inc is a clinical-stage biopharmaceutical company focused on developing adaptive and controllable cell therapies for the treatment of patients with cancer and other incurable diseases. The company's proprietary technology platform utilizes novel synthetic binding domains to engineer cell therapies that can be controlled post-infusion.
Over the past year, the insider has sold a total of 9,000 shares of Arcellx Inc and has not made any purchases of the stock. The insider transaction history for the company shows a pattern of 22 insider sells and no insider buys over the same timeframe.
On the date of the insider's recent transaction, shares of Arcellx Inc were trading at $70.4 each, which places the company's market cap at approximately $3.648 billion.
The insider's recent sale contributes to the ongoing trend of insider selling at Arcellx Inc, with no insider purchases reported over the past year. This information may be of interest to shareholders and potential investors as they consider the insider activity as one of many factors in their investment decisions.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
